Clinical trials: Reduced Left Ventricular Ejection Fraction
Heart Failure With Reduced Ejection Fraction
Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction
To evaluate pharmacokinetics (PK) of omecamtiv mecarbil in Japanese subjects with heart failure (HF) with reduced ejection fraction To evaluate the safety and tolerability of oral omecamtiv mecarbil
- Trial name
- NCT02695420
- Testing
- 25 mg Omecamtiv Mecarbil, 37.5 mg Omecamtiv Mecarbil, 50 mg Omecamtiv Mecarbil
- Where
- 32 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Cytokinetics
Heart Failure With Reduced Ejection Fraction (HFrEF)
A Trial of CRD-4730 in HFrEF
CRD-4730 is a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor. The CALIBRATE-HF trial is a Phase 2, global, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial.
- Trial name
- CALIBRATE-HF (NCT07750873)
- Testing
- CRD-4730
- Where
- 2 sites in United States
- Volunteers
- 525 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Heart Failure, Central Sleep Apnea
Central Sleep Apnea Prevalence and Impact on Cognitive Function in Patients With Heart Failure With Reduced or Mildly Reduced Left Ventricular Ejection Fraction
Study to assess the prevalence of central sleep apnea in patients with heart failure with reduced or mildly reduced left ventricular ejection fraction (LVEF <50%) followed by case-control study to assess the link between central…
- Trial name
- COG01 (NCT06313840)
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Zoll Medical Corporation
Heart Failure With Reduced Ejection Fraction
Vsling™ I: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure
Prospective, multi-center, open-label clinical study of the feasibility and initial safety and performance of the Vsling™ in patients with heart failure (HF) with evidence of reduced left ventricular ejection fraction, associated…
- Trial name
- NCT06851949
- Testing
- Vsling
- Where
- 5 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Cardiac Success
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the effect of IONIS-AGT-LRX weekly subcutaneous (SC) injection on plasma angiotensinogen (AGT) concentration from Baseline to Study Day 85 (Week 13) and to evaluate the effect of…
- Trial name
- ASTRAAS-HF (NCT04836182)
- Testing
- IONIS-AGT-LRx
- Where
- 19 sites in United States, Hungary and 1 more
- Volunteers
- 72 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Left Ventricular Dysfunction, Ventricular Dysfunction
Low Ejection Fraction in Single Lead ECG- Ochsner
The purpose of this research is to prospectively test and validate the single-lead Low EF algorithm in outpatients in order to test the performance of a single-lead ECG based algorithm to identify people with decreased left…
- Conditions
- Left Ventricular Dysfunction, Ventricular Dysfunction, Heart Diseases, Cardiovascular Diseases
- Trial name
- NCT05010642
- Testing
- Use of Eko DUO electronic Stethoscope
- Where
- United States
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Eko Devices, Inc.
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
This study will evaluate the V-Wave Ventura Interatrial shunt. The Shunt is a small, hourglass-shaped device implanted in the dividing wall (septum) between the right and left atria (top chambers) of the heart placed during a…
- Conditions
- Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic, Heart Failure New York Heart Association Class III, Heart Failure Congestive
- Trial name
- RELIEVE-HFrEF (NCT07696975)
- Testing
- Implantation of the V-Wave Interatrial shunt
- Volunteers
- 250 people
- Sponsor
- V-Wave Ltd
Obesity, Heart Failure
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body…
- Trial name
- HF-POLARIS (NCT07567001)
- Testing
- NNC0487-0111
- Where
- 838 sites in United States, Argentina and 25 more
- Volunteers
- 5,610 people
- Sponsor
- Novo Nordisk A/S
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
The purpose of this study was to assess the effect of LCZ696 at a target dose of 200 mg b.i.d. compared to enalapril 10 mg b.i.d., in addition to the background heart failure (HF) treatment, on delaying time to first occurrence…
- Trial name
- PARALLEL-HF (NCT02468232)
- Testing
- LCZ696, Enalapril
- Where
- 49 sites in Japan
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Left Ventricular Dysfunction
Detection of Heart Conditions With Single Lead ECG Using Artificial Intelligence
The purpose of this research is to prospectively test and validate the single-lead Low EF algorithm in outpatients in order to test the performance of a single-lead ECG based algorithm to identify people with decreased left…
- Trial name
- DAVID1 (NCT04400435)
- Testing
- Use of Eko DUO electronic stethoscope
- Where
- 3 sites in United States
- Volunteers
- 1,258 people
- Sponsor
- Eko Devices, Inc.
Cardiomyopathy, Dilated, Heart Failure
The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor
Chronic heart failure (CHF) is one of the major causes of death in Western societies. Evidence has accumulated that functionally active autoantibodies directed against the beta1 adrenergic receptor (β1 AAb) are of…
- Conditions
- Cardiomyopathy, Dilated, Heart Failure, Autoantibodies
- Trial name
- NCT04192214
- Testing
- BC 007
- Where
- 3 sites in Serbia
- Volunteers
- 30 people
- Sponsor
- Berlin Cures GmbH
Heart Failure, Systolic
Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells
This clinical study will utilize allogenic bone marrow-derived culture-expanded MSC that are expanded from mesenchymal stem cells and delivered using the investigational Helix transendocardial delivery catheter as a therapy for…
- Trial name
- CardiALLO (NCT05925608)
- Testing
- CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs), Diagnostic Catheterization
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- BioCardia, Inc.
Heart Failure
Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages.
- Trial name
- EVOLUTION-HF (NCT05465213)
- Where
- 8 sites in Portugal
- Volunteers
- 283 people
- Sponsor
- AstraZeneca